Every trade that managers of Allergy Therapeutics Plc disclose to RNS (LSE) is tracked on this page. Nothing new has been filed by managers of Allergy Therapeutics Plc in twelve months, the latest record being from 15 January 2025.
Looking back to 2025, when coverage begins, insiders filed 2 purchases and no sales.
This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
Analysts rate Allergy Therapeutics Plc Strong Buy (bullish), based on 1 analysts. Average price target: £0.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2025 · cache
2 of 2 declarations
Allergy Therapeutics Plc is a company focused on developing immunotherapy treatments for allergies. It is listed on the London Stock Exchange.